Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
Abstract Background Fatty liver is associated with obesity, type 2 diabetes, hyperlipidemia, hypertension, and metabolic syndrome. While there are no approved drugs for the treatment of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis, strategies to ameliorate fatty liver oft...
Main Authors: | Ian Blazina, Shelley Selph |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Systematic Reviews |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13643-019-1200-8 |
Similar Items
-
Treatment Options in Non-alcoholic Fatty Liver Disease
by: Won Kim
Published: (2017-06-01) -
Advances in the treatment of nonalcoholic fatty liver disease
by: FENG Gong
Published: (2017-12-01) -
Potential therapeies for nonalcoholic fatty liver disease
by: XIE Xiao
Published: (2017-12-01) -
Application of lipid-regulating drugs in prevention and treatment of nonalcoholic fatty liver disease
by: LU Bingjie
Published: (2017-12-01) -
Research advances in intestinal flora in nonalcoholic fatty liver disease
by: LIU Jiaqi
Published: (2017-12-01)